Hironori Koga

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/390038/publications.pdf

Version: 2024-02-01

62 papers	2,320 citations	257450 24 h-index	214800 47 g-index
63 all docs	63 docs citations	63 times ranked	3405 citing authors

#	Article	IF	Citations
1	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrastâ€enhanced ultrasound. Cancer Reports, 2022, 5, e1471.	1.4	7
2	Usefulness of a novel transarterial chemoinfusion plus externalâ€beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. Cancer Reports, 2022, 5, e1539.	1.4	3
3	Effects of <scp>SGLT2</scp> inhibitor on tumorâ€releasing chemokines/cytokines in <scp>Hep3B</scp> and <scp>Huh7</scp> cells. JGH Open, 2022, 6, 270-273.	1.6	0
4	Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma. Clinical and Molecular Hepatology, 2022, 28, 575-579.	8.9	6
5	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers, 2022, 14, 2295.	3.7	3
6	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 2021, 13, 160.	3.7	38
7	Efficacy of a Glass Membrane Emulsification Device to Form Mixture of Cisplatin Powder with Lipiodol on Transarterial Therapy for Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2021, 44, 766-773.	2.0	3
8	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers, 2021, 13, 646.	3.7	19
9	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine, 2021, 10, 987.	2.4	7
10	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 2021, 13, 2786.	3.7	44
11	Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers, 2021, 13, 4450.	3.7	10
12	Firstâ€line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Medicine, 2021, 10, 8530-8541.	2.8	12
13	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers, 2021, 13, 5282.	3.7	11
14	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers, 2020, 12, 1867.	3.7	56
15	Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). PLoS ONE, 2020, 15, e0232283.	2.5	32
16	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. Nutrients, 2020, 12, 1076.	4.1	27
17	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers, 2020, 12, 1010.	3.7	42
18	Promotion of liver regeneration and antiâ€fibrotic effects of theÂTGFâ€Î² receptor kinase inhibitor galunisertib in CCl4â€treated mice. International Journal of Molecular Medicine, 2020, 46, 427-438.	4.0	13

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0232283.		0
20	Title is missing!. , 2020, 15, e0232283.		0
21	Title is missing!. , 2020, 15, e0232283.		0
22	Title is missing!. , 2020, 15, e0232283.		0
23	Title is missing!. , 2020, 15, e0232283.		0
24	Title is missing!. , 2020, 15, e0232283.		0
25	Effects of inâ€hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 580-588.	2.8	41
26	High serum interleukinâ€34 level is a predictor of poor prognosis in patients with nonâ€viral hepatocellular carcinoma. Hepatology Research, 2019, 49, 1046-1053.	3.4	21
27	Predictors of hepatocellular carcinoma recurrence associated with the use of directâ€acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. Cancer Medicine, 2019, 8, 2646-2653.	2.8	27
28	Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer. Medical Molecular Morphology, 2019, 52, 198-208.	1.0	36
29	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatology International, 2019, 13, 293-301.	4.2	38
30	Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesisâ€related cytokines after treatment with sodiumâ€glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus. Hepatology Research, 2019, 49, 479-486.	3.4	23
31	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. Oncology, 2019, 96, 192-199.	1.9	4
32	Development and validation of sensitive and selective quantification of total and free daptomycin in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2019, 165, 56-64.	2.8	13
33	Ultrasound-guided central venous tip confirmation via right external jugular vein using a right supraclavicular fossa view. Journal of Vascular Access, 2019, 20, 19-23.	0.9	6
34	High expression of <scp>CD</scp>44v9 and <scp>xCT</scp> in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. Cancer Science, 2018, 109, 2801-2810.	3.9	63
35	Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1. Molecular Cancer Research, 2017, 15, 744-752.	3.4	35
36	Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. Journal of Hepatology, 2017, 66, 142-152.	3.7	312

#	Article	IF	Citations
37	Clinical effects and safety of intraâ€‘arterial infusion therapy of cisplatin suspension in lipiodol combined with 5â€‘fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extraâ€‘hepatic spread: A prospective cohort study. Molecular and Clinical Oncology, 2017, 7, 1013-1020.	1.0	27
38	Pancreatic DCLK1 marks quiescent but oncogenic progenitors: a possible link to neuroendocrine tumors. Stem Cell Investigation, 2016, 3, 37-37.	3.0	5
39	Ex vivo expansion of circulating CD34+ cells enhances the regenerative effect on rat liver cirrhosis. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16025.	4.1	8
40	The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation. Journal of Critical Care, 2016, 36, 29-34.	2.2	25
41	Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2016, 77, 243-250.	2.3	21
42	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Medicine, 2015, 4, 1836-1843.	2.8	54
43	High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors. Oncology Letters, 2015, 10, 2015-2020.	1.8	15
44	Toxicity of Parasporin-4 and Health Effects of Pro-parasporin-4 Diet in Mice. Toxins, 2014, 6, 2115-2126.	3.4	5
45	Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis. Hepatology International, 2013, 7, 767-774.	4.2	23
46	New Î±-Lipoic Acid Derivative, DHL-HisZn, Ameliorates Renal Ischemia-Reperfusion Injury in Rats. Journal of Surgical Research, 2012, 174, 352-358.	1.6	25
47	Hepatitis C virus core protein upregulates the expression of vascular endothelial growth factor via the nuclear factor-ÎºB/hypoxia-inducible factor-1Î± axis under hypoxic conditions. Hepatology Research, 2012, 42, 591-600.	3.4	36
48	Loss of the SxxSS Motif in a Human T-Cell Factor-4 Isoform Confers Hypoxia Resistance to Liver Cancer: An Oncogenic Switch in Wnt Signaling. PLoS ONE, 2012, 7, e39981.	2.5	15
49	PPARÎ³ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. International Journal of Oncology, 2011, 40, 679-85.	3.3	18
50	Human Atrial Natriuretic Peptide Ameliorates LPS-Induced Acute Lung Injury in Rats. Lung, 2010, 188, 241-246.	3.3	9
51	Switching in discoid domain receptor expressions in SLUGâ€induced epithelialâ€mesenchymal transition. Cancer, 2008, 113, 2823-2831.	4.1	45
52	Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. Journal of Hepatology, 2007, 47, 93-102.	3.7	67
53	Luteolin Promotes Degradation in Signal Transducer and Activator of Transcription 3 in Human Hepatoma Cells: An Implication for the Antitumor Potential of Flavonoids. Cancer Research, 2006, 66, 4826-4834.	0.9	188
54	Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology, 2003, 37, 136-147.	7.3	71

#	Article	IF	Citations
55	Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology, 2003, 37, 1086-1096.	7.3	58
56	Hepatocellular carcinoma: Is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?. Cancer, 2003, 98, 661-667.	4.1	38
57	Prognostic significance of the F-box protein Skp2 expression in diffuse large B-cell lymphoma. American Journal of Hematology, 2003, 73, 230-235.	4.1	53
58	Abnormal accumulation in lipopolysaccharide in biliary epithelial cells of rats with self-filling blind loop. International Journal of Molecular Medicine, 2002, 9, 621.	4.0	10
59	Involvement of p21WAF1/CIP1 and p27KIP1 in Troglitazone-Induced Cell Cycle Arrest in Human Hepatoma Cell Lines. , 2002, , 61-72.		0
60	Abnormal accumulation in lipopolysaccharide in biliary epithelial cells of rats with self-filling blind loop. International Journal of Molecular Medicine, 2002, 9, 621-6.	4.0	16
61	Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology, 2001, 33, 1087-1097.	7.3	141
62	Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology, 1999, 29, 688-696.	7.3	395